Articles

Bone-targeted therapies in prostate cancer

BJMO - volume 10, issue 3, may 2016

P. Dirix MD, PhD, P. Westerlinck MD, G. Buelens MD, P. Huget MD, P. Meijnders MD, PhD

Summary

Skeletal involvement is very common in metastatic prostate cancer and is associated with (symptomatic) skeletal-related events. This article examines the clinical trial data that support the use of available bone-targeted therapies in prostate cancer.

(BELG J MED ONCOL 2016;10(3):97–100)

Read more
X